Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 15;16(4):e0249817. doi: 10.1371/journal.pone.0249817

Ingestion of Bifidobacterium longum changes miRNA levels in the brains of mice

Laura DeVries 1,#, Cara Horstman 1,¤a,#, Marie Fossell 1,¤b, Clayton Carlson 1,*
Editor: Gulcin Avci2
PMCID: PMC8049326  PMID: 33857178

Abstract

The purpose of this research is to investigate the relationship between the microbiota of the gastrointestinal (GI) system and relative gene expression of miRNAs and mRNAs in the brain. C57BL/6 mice and Balb/c mice are fed Bifidobacterium longum, a well-characterized probiotic bacterial species shown to change behavior and improve sociability of Balb/c mice. After feeding, RNA was extracted from whole brains and PCR arrays were utilized to determine changes in the gene expression of brain-specific miRNAs. The results of these PCR arrays reveal that the relative gene expression of mmu-mir-652-3p is sensitive to B. longum probiotic treatment in C57BL/6 mice. qPCR was performed to measure expression of Dab1, an mRNA target of this miRNA. Dab1 expression is also dependent on B. longum. The goal of this study is to further understand the relationship between the gut microbiota and its impacts on neurological gene expression and brain function.

Introduction

The Microbiota-Gut-Brain axis is the bidirectional relationship between microbes living in the gut and the brain of their host [1]. Nearly 3,000 different prokaryotic species have been identified from human fecal material [2, 3]. Beyond their involvement in digestive health, these bacteria have been shown to be able to influence health, neurodevelopment, and behavior [4]. Experiments in rodents demonstrate that the gut microbiota can interact with the brain through numerous mechanisms including small molecules, the immune system, and the enteric nervous system.

Studies of blood metabolites in germ free mouse models have shown that the gut microbiota produces a number of important physiologically active metabolites [57]. Among these are short-chain fatty acids. Short-chain fatty acids produced by gut microbes include acetate, propionate, and butyrate. Changes to the fecal concentration of these molecules are associated with numerous neurological conditions including Parkinson’s disease and Autism Spectrum Disorder (ASD) [8].

Additionally, the gut microbiota interacts constantly with the host immune system. The neurological consequences of this interaction is an active area of research, but it is thought that the gut microbiota may regulate neuroinflammation through disruption of monocyte recruitment [9]. Likewise, the adaptive immune system has key roles in both the brain and the gut microbiota and the makeup of the gut microbiota seems to impact the activity of the adaptive immune system in the brain [10, 11].

The gut microbiota also communicates with the nervous system directly. Metabolites made by the gut microbiota including tryptophan metabolites, serotonin, GABA, and catecholamines which are all able to activate the autonomic nervous system and influence brain activity through the vagus nerve [12]. These metabolites also stimulate and shape the enteric nervous system, the complex web of neurons that largely controls the gastrointestinal tract. Interestingly, many disorders associated with the brain also display changes to the enteric nervous system including Parkinson’s disease, ASD, and Alzheimer’s [13].

While it may not be surprising considering the number of connections in the microbiota-gut-brain axis, changes to the gut microbiota impact a wide range of behaviors including food intake, stress behavior, sociality and more, though much work still needs to be done [14]. For each of these behavioral changes, the complete mechanistic pathway from bacterial population to behavioral change has yet to be determined, but the study of so called psychobiotics continues to become clearer.

One example involves treating mice exposed to chronic stress with a combination of two psychobiotics, Lactobacillus helveticus and Bifidobacterium longum [15]. Mice treated with these bacteria showed changes in the expression of key transcription factors in the brain and increases in neurogenesis and brain plasticity as compared to mice that received a control bacteria species. These bacteria seem to help regulate stress response [15].

Balb/c mice are inherently anxious and display behavioral differences when compared to the C57BL/6 strain [16]. Changing the gut microbiota can impact behavior of Balb/c mice. For example, six week treatment with either of two species of Bifidobacterium reduced stress behaviors in Balb/c mice [17]. In addition to reducing overall stress behaviors, B. longum showed a positive role in the Balb/c mouse response to acute stress and depression.

These results indicate that psychobiotics like Bifidobacterium longum can improve behavior in Balb/c mice, but many steps in the mechanistic pathway between the microbe and the behavior remain a mystery. For example, while the gut bacteria is known to regulate the expression of miRNAs in the brains of germ free mouse models [18], the impact of B. longum on gene expression of miRNAs in the brain of Balb/c mice has not yet been explored.

In the current study, Balb/c and C57BL/6 mice were treated with B. longum and the expression of a set of brain miRNAs was measured. We have identified differences in the expression of a miRNA involved in neurological development and a corresponding deviation in the expression of an mRNA that shapes brain structure that is targeted by this miRNA.

Methods

Our work involved sacrifice of mice by cervical dislocation. This project was prospectively reviewed, approved, and then observed by the Trinity Christian College Animal Research Advisory Group. We do not have a permit number.

Bacterial growth

Bifidobacterium longum subsp. longum Reuter (ATCC 15707) was grown anaerobically in Sigma-Aldrich MRS broth with Tween 80 and L-cysteine and frozen in 100μL aliquots representing 109 cells per tube. Tubes of MRS media with Tween 80 and L-cysteine were also frozen for controls.

Mice

Twenty-one day old C57BL/6 and Balb/c mice strains were obtained from Charles River Laboratories. The mice were divided into the following four categories according to their strain and type of bacterial feeding: C57BL/6—Control, C57BL/6—Bifidobacterium, Balb/c—Control, and Balb/c—Bifidobacterium. There were four mice in each group for a total of 16 animals. The animals were kept in cages in a climate controlled environment with 12hrs of light and 12hrs of darkness. Mice in each experimental condition were kept in a cage together. Four cages with four mice each. This is the minimum number of animals we were comfortable using in this experiment. Once daily, the mice were fed either 100 μL of 109 B. longum or 100μL of media. The order in which the mice were fed, and the placement of the cages was rotated daily. The presence of B. longum in the bowel was not measured for any mice with or without treatment. All researchers were aware of which mice were receiving bacteria and which were receiving media. After 22 days of bacterial feeding, the mice were euthanized by cervical dislocation and death was assessed before brains were harvested. All four mice, from all four conditions (sixteen in total) were euthanized. No mice were excluded from the collection and RNA extraction because no criteria were determined a priori for their exclusion.

RNA preparation and collection

Individual brains were placed in Qiagen RNAlater RNA Stabilization Reagent to stop gene expression. The RNA of each whole brain was harvested using a Qiagen RNeasy Mini Kit following the vendor’s instructions.

cDNA synthesis

cDNA was synthesized for each mouse brain using Qiagen miScript II RT Kit following the vendor’s instructions for miRNA enrichment. No mice were excluded from the cDNA synthesis, so four mice from each condition, sixteen total, were synthesized.

Gene expression–PCR arrays

MicroRNAs that are involved in neurological development and disease were measured for each mouse group using the miScript miRNA PCR Array Mouse Neurological Development and Disease (MIMM 107ZD-12). Using the miScript miRNA PCR Array, 12.5 μL of each cDNA sample within a mouse group was added to the same PCR Master Mix. cDNA from the four mice in the same group were pooled. The Master Mix was thoroughly mixed with a pipette and 25 μL was pipetted into each individual well of the miScript miRNA PCR Array. The plate was run according to the Qiagen’s instructions. Briefly, the plate was run at 95˚C for 15 minutes then cycled through 40 rounds of 94˚C for 15 seconds, 55˚C for 30 seconds, and 70˚C for 30 seconds. Each treatment group (of four pooled samples) was assayed four times yielding four technical replicates of the pooled samples. Data analysis was completed using the Qiagen Data Analysis Centre with normalization by automatic selection from the full plate.

Gene expression–miRNA qPCR and mRNA qPCR

Based on the changes of gene expression found in the Neurological qPCR arrays, a gene of interest, miR-652, was investigated based on its association with autism spectrum disorder. A more nuanced measurement of this gene’s expression was performed using each biological replicate. Isolated RNA from each mouse replicate was reverse transcribed to form miRNA-enriched cDNA using Qiagen miScript II RT Kit and the manufacturer’s instructions.

The expression of mmu-mir-652-3p was measured using Qiagen 10x miScript Mm_miR-652_3 (MS00012425) primer assay. qPCR was completed using QuantiTect SYBR Green PCR Master Mix according to the vendor’s instructions. Samples were compared to a control primer assay (RNU6).

In order to measure expression of an mRNA target of mmu-mir-652-3p, isolated RNA from each mouse brain replicate was reverse transcribed to form mRNA-enriched cDNA using Qiagen miScript II RT Kit and the manufacturer’s instructions. The mRNA-enriched cDNA was measured by qPCR using QuantiTect SYBR Green PCR Master Mix. No mice were excluded from these experiments. There were four biological replicates and four technical replicates for each reaction.

Results, discussion, conclusions

B. longum changes expression of miRNAs in the brain

To determine the effect of the gut microbiota on expression of miRNAs in the brain of mice, two different strains of mice were fed approximately one billion B. longum daily for three weeks. The expression of brain miRNAs for C57BL/6 and Balb/c mice was measured using Qiagen PCR arrays. These arrays test the expression of miRNAs involved in neurological development and health.

The two strains of mice show similar levels of expression over a set of 80 different important miRNAs (Fig 1), but, as expected, numerous miRNAs are expressed differently in the two strains of mice. miRNAs expressed more strongly in Balb/c mice than in C57BL/6 mice are shown in Table 1. These data suggest that there are differences in expression of regulatory RNAs in the brain in addition to the reported behavioral differences between these two strains of mice published previously [16].

Fig 1. Balb/c and C57BL/6 mice express some brain miRNAs differently.

Fig 1

When 84 miRNAs were tested using a PCR array, many miRNAs are expressed similarly in both strains of mice. However, some genes show differences expression in Balb/c as compared to C57BL/6 mice. Those with greater than 2-fold difference in expression are highlighted in grey. mmu-mir-652-3p is marked with a square (see below).

Table 1. List of genes with more than 2-fold difference in expression levels in Balb/c and C57BL/6 mice.

Gene Balb/c relative expression C57BL/6 relative expression Balb/c Fold expression over C57BL/6
mmu-mmu-mir-652-3p 0.317 0.012 25.72
mmu-miR-33-5p 1.152 0.310 3.72
mmu-miR-328-3p 0.258 0.076 3.4
mmu-miR-431-5p 0.119 0.037 3.22
mmu-miR-26b-5p 11.988 3.755 3.19
mmu-miR-320-3p 0.194 0.069 2.8
mmu-miR-30e-5p 9.670 3.834 2.52
mmu-miR-338-3p 4.769 1.904 2.51
mmu-miR-138-5p 6.885 2.865 2.4
mmu-miR-485-5p 0.105 0.045 2.32
mmu-miR-181a-5p 1.314 0.586 2.24
mmu-miR-20b-5p 0.115 0.052 2.21
mmu-miR-146b-5p 0.278 0.128 2.18
mmu-miR-433-3p 0.214 0.099 2.17
mmu-miR-181c-5p 0.885 0.426 2.08
mmu-miR-107-3p 0.328 0.159 2.06

In order to determine whether, and to what extent, short term probiotic usage could influence miRNA expression in the brain, Balb/c and C57BL/6 mice were fed approximately 109 B. longum daily for three weeks. In both Balb/c and C57BL/6 mice, three weeks of daily feeding of the probiotic led to differences in expression of miRNAs that are important for neurological development and health (Fig 2). miRNAs that show at least 1.5-fold change in expression level in both strains of mice are reported in Table 2. This supports previous work that has shown that gene expression in the brain is influenced by the gut microbiota through the microbiota-gut-brain axis [18].

Fig 2. B. longum changes neurologically relevant miRNA expression in both Balb/c and C57BL/6 mice.

Fig 2

Mice that have been fed 109 B. longum for three weeks show changes in expression of some neurologically relevant miRNAs in the brain. PCR arrays of miRNAs from the brains of C57BL/6 (top) and Balb/c (bottom) mice reveal that the bacteria does seem to influence gene expression of miRNAs in the brain. Those with greater than 2-fold difference in expression are highlighted in grey. mmu-mir-652-3p is marked with a square in the top graph (see below).

Table 2. miRNAs that are at least 1.5-fold different in mice that are fed B. longum versus those that are fed only media.

Gene Balb/c change in expression C57BL/6 change in expression
mmu-let-7b-5p 2.79 2.18
mmu-let-7e-5p 1.54 2.4
mmu-miR-130a-3p 1.92 1.95
mmu-miR-181a-5p 1.87 2.12
mmu-miR-181c-5p 2.00 1.54
mmu-miR-20b-5p 1.56 5.63
mmu-miR-298-5p 1.75 1.86
mmu-miR-29c-3p 1.56 1.93
mmu-miR-320-3p 1.54 2.52
mmu-miR-346-5p 1.95 2.3

All genes listed showed a change in both mouse strains tested.

B. longum reduces differences in miRNA levels in the brain of Balb/c and C57BL/6 mice

In order to determine whether the changes in miRNA expression associated with B. longum feeding can normalize expression between Balb/c and C57BL/6 mice, the level of miRNAs in mice of both strains after treatment with the probiotic were compared. After three weeks of treatment, Balb/c and C57BL/6 mice expressed brain miRNAs very similarly. Many miRNAs that are expressed differently when comparing the two strains of mice without probiotics show substantially more similar gene expression when treated with the probiotic (Fig 3). Most of the changes occur in the C57BL/6 mice. Of particular interest is the miRNA mmu-mir-652-3p, a regulatory RNA that has been implicated in human neurodevelopmental conditions like ASD [19]. According to the array data, Balb/c mice without B. longum treatment express mmu-mir-652-3p at much higher levels than C57BL/6 mice. However, with the probiotic, the levels of mmu-mir-652-3p is essentially indistinguishable between Balb/c and C57BL/6 mice. Both mice seem to display the higher level of gene expression for mmu-mir-652-3p.

Fig 3. Expression of miRNA in the brains of mice with B. longum treatment.

Fig 3

Expression of brain miRNAs were measured using a PCR array screening of miRNAs associated with neurological development and health. Without treatment, some miRNAs, including mmu-mir-652-3p, are expressed differently in Balb/c and C57BL/6 mice (see Fig 1). With treatment, expression of most miRNAs tested align between the two strains of mice.

To confirm the difference in mmu-mir-652-3p expression upon treatment with B. longum, qPCR was performed, testing expression of the single miRNA (Fig 4). Three-week treatment with B. longum significantly decreased expression of mmu-mir-652-3p in Balb/c mice, but not C57BL/6 mice. This change was unexpected given the array results, but the final conclusion is the same. These results indicate that B. longum could normalize expression of developmentally important miRNAs like, mmu-mir-652-3p, between Balb/c and C57BL/6 mice.

Fig 4. Expression of mmu-mir-652-3p in the brains of mice with and without B. longum treatment.

Fig 4

Expression of mmu-mir-652-3p in the brains of Balb/c and C57BL/6 mice was measured using a qPCR. Values are relative to Hs-RNU6-2 and error bars represent one standard deviation. The change in expression in the Balb/c mice is statistically significant (p<0.05). n = 4 per bar.

Consequences of B. longum induced miRNA levels

In order to evaluate the consequences of the different expression level of these miRNAs with B. longum, we measured the expression of Dab1, Disabled-1 (NCBI Gene ID: 13131), an mRNA targeted by mmu-mir-652-3p. Dab1 is involved in cell positioning and higher order brain structure during fetal development. Based on regulatory RNA activity, changes in the expression levels of miRNA are likely to influence gene expression of the mRNAs that they target. We used qPCR to measure the levels of Dab1 mRNA. In C57BL/6 mice, which according to the PCR data have no discernable differences in expression of mmu-mir-652-3p upon treatment, Dab1 seems to have no difference in expression levels with or without treatment with B. longum. In contrast, in Balb/c mice, which show a marked decrease in expression of the repressor mmu-mir-652-3p in qPCR, there is a corresponding increase in the levels of Dab1 mRNA (Fig 5). These results are consistent with the hypothesis that feeding mice B. longum causes a decreased expression of the repressor mmu-mir-652-3p which permits higher levels of Dab1 mRNA.

Fig 5. Dab1 mRNA levels in the brains of mice with and without B. longum treatment.

Fig 5

Expression of Dab1 in the brains of Balb/c and C57BL/6 mice was measured using a qPCR. Values are relative to Rer1 control and error bars represent one standard deviation. The change in expression in Balb/c mice is statistically significant (p<0.05). n = 4 per bar.

General conclusion

As the profound interactions between the gut microbiota and the structure, chemistry, and activity of the brain continue to be discovered, the functional details of how the microbiota-gut-brain-axis works are starting to be resolved. Previous studies have suggested B. longum can cause changes in brain chemistry and activity [20]. Other research has revealed that modifications to expression of Dab1 early in life can have cause lasting changes in behavior of adult mice [21]. Our study, while based on a small sample size, adds further evidence that digestive probiotics can influence miRNAs that in turn regulate expression of important neurological mRNAs. Our data are consistent with a mechanism in which B. longum decreases expression of miRNA 652-3p (by a process that has not yet been revealed) and the reduced levels of miRNA 652-3p lead to increased mRNA stability of Dab1 which in turn changes behavior in adult Balb/c mice. There is still much to be clarified about the complex interactions of the microbiota-gut-brain axis, but the activity of miRNAs could be one mechanism by which gut microbes are able to impact brain activity.

Supporting information

S1 Data

(XLS)

S1 Table. PCR array data.

This table contains the complete data set from the PRC arrays.

(PDF)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The study was supported by the Trinity Christian College with Honors awarded to Laura DeVries and Cara Horstman. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Cryan JF, O’riordan KJ, Cowan CSM, Sandhu K V., Bastiaanssen TFS, Boehme M, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99: 1877–2013. 10.1152/physrev.00018.2018 [DOI] [PubMed] [Google Scholar]
  • 2.Hugon P, Dufour J-C, Colson P, Fournier P-E, Sallah K, Raoult D. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15: 1211–1219. 10.1016/S1473-3099(15)00293-5 [DOI] [PubMed] [Google Scholar]
  • 3.A Catalog of Reference Genomes from the Human Microbiome. Science (80-). 2010;328: 994 LP– 999. 10.1126/science.1183605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cryan JF, Dinan TG. More than a gut feeling: the microbiota regulates neurodevelopment and behavior. Neuropsychopharmacology. 2015;40: 241. 10.1038/npp.2014.224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci. 2009;106: 3698–3703. 10.1073/pnas.0812874106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mishima E, Ichijo M, Kawabe T, Kikuchi K, Akiyama Y, Toyohara T, et al. Germ-Free Conditions Modulate Host Purine Metabolism, Exacerbating Adenine-Induced Kidney Damage. Toxins (Basel). 2020;12: 547. Available: 10.3390/toxins12090547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489: 242–249. Available: 10.1038/nature11552 [DOI] [PubMed] [Google Scholar]
  • 8.Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated Fecal Short Chain Fatty Acid and Ammonia Concentrations in Children with Autism Spectrum Disorder. Dig Dis Sci. 2012;57: 2096–2102. 10.1007/s10620-012-2167-7 [DOI] [PubMed] [Google Scholar]
  • 9.Wohleb ES, McKim DB, Sheridan JF, Godbout JP. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior [Internet]. Frontiers in Neuroscience. 2015. p. 447. Available: 10.3389/fnins.2014.00447 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rojas OL, Pröbstel A-K, Porfilio EA, Wang AA, Charabati M, Sun T, et al. Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell. 2019;176: 610–624.e18. 10.1016/j.cell.2018.11.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Smith CJ, Emge JR, Berzins K, Lung L, Khamishon R, Shah P, et al. Probiotics normalize the gut-brain-microbiota axis in immunodeficient mice. Am J Physiol Liver Physiol. American Physiological Society; 2014;307: G793–G802. 10.1152/ajpgi.00238.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain–gut–enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6: 306–314. 10.1038/nrgastro.2009.35 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rao M, Gershon MD. The bowel and beyond: the enteric nervous system in neurological disorders. Nat Rev Gastroenterol Hepatol. 2016;13: 517–528. 10.1038/nrgastro.2016.107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Romijn AR, Rucklidge JJ. Systematic review of evidence to support the theory of psychobiotics. Nutr Rev. 2015;73: 675–693. 10.1093/nutrit/nuv025 [DOI] [PubMed] [Google Scholar]
  • 15.Ait-Belgnaoui A, Colom A, Braniste V, Ramalho L, Marrot A, Cartier C, et al. Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice. Neurogastroenterol Motil. John Wiley & Sons, Ltd; 2014;26: 510–520. 10.1111/nmo.12295 [DOI] [PubMed] [Google Scholar]
  • 16.Heinla I, Åhlgren J, Vasar E, Voikar V. Behavioural characterization of C57BL/6N and BALB/c female mice in social home cage–Effect of mixed housing in complex environment. Physiol Behav. 2018;188: 32–41. 10.1016/j.physbeh.2018.01.024 [DOI] [PubMed] [Google Scholar]
  • 17.Savignac HM, Kiely B, Dinan TG, Cryan JF. Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. Neurogastroenterol Motil. John Wiley & Sons, Ltd; 2014;26: 1615–1627. 10.1111/nmo.12427 [DOI] [PubMed] [Google Scholar]
  • 18.Hoban AE, Stilling RM, M. Moloney G, Moloney RD, Shanahan F, Dinan TG, et al. Microbial regulation of microRNA expression in the amygdala and prefrontal cortex. Microbiome. 2017;5: 102. 10.1186/s40168-017-0321-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Abu-Elneel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, Geschwind DH, et al. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics. 2008;9: 153–161. Available: 10.1007/s10048-008-0133-5 [DOI] [PubMed] [Google Scholar]
  • 20.Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut–brain communication. Neurogastroenterol Motil. John Wiley & Sons, Ltd; 2011;23: 1132–1139. 10.1111/j.1365-2982.2011.01796.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Teixeira CM, Masachs N, Muhaisen A, Bosch C, Pérez-Martínez J, Howell B, et al. Transient Downregulation of Dab1 Protein Levels during Development Leads to Behavioral and Structural Deficits: Relevance for Psychiatric Disorders. Neuropsychopharmacology. 2014;39: 556–568. Available: 10.1038/npp.2013.226 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Gulcin Avci

24 Feb 2021

PONE-D-20-38290

Ingestion of Bifidobacterium longum changes miRNA levels in the brains of mice

PLOS ONE

Dear Dr. Clayton,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

A major revision decision has been made for your article in line with the referee comments. The referee reports are attached. Your letter can be re-evaluated after making the necessary arrangements as a result of the referee comments.

==============================

Please submit your revised manuscript by 10 March. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Gulcin Avci

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: There are several minor comments, which should be addressed in order to improve quality of the paper:

Line 32: please add the references which studies demonstrated these mechanism

Line 36: “Studies of blood metabolites…” but you add only a reference. Please revise it.

Line 154-156: “These data suggest that in addition to the reported behavioral differences between these two strains of mice, there are also differences in expression of regulatory RNAs in the brain [12] Is this your results or Savignac et al. 2014? It is not understandable. Please revişe it.

The discussion section in this study is very poor. Author should be revised the discussion section extensively.

Author used the only fifteen literatures in the manuscript, because they did not discuss their results with other studies. The authors need to do a better job at explaining the necessity of this work and the importance of their conclusions. Presenting of the results and the discussion is generally poor.

Reviewer #2: Dear Authors,

Thank you for your interesting manuscript.

please answer my questions and concerns regarding the study:

1. How can you confirm that the bowel flora of the mice was the same the commencing stage?

2. Why mir-652, was the selected mir? Can you please give a reference for this decision?

3. Did you prove the level of microbiota in the mice bowel before and after trial? The level could be different in each mouse before and after trial and it could affect the results

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Shahram Agah

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Gulcin Avci

26 Mar 2021

Ingestion of Bifidobacterium longum changes miRNA levels in the brains of mice

PONE-D-20-38290R1

Dear Dr. Clayton Carlson,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gulcin Avci

Academic Editor

PLOS ONE

Acceptance letter

Gulcin Avci

5 Apr 2021

PONE-D-20-38290R1

Ingestion of Bifidobacterium longum changes miRNA levels in the brains of mice

Dear Dr. Carlson:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Gulcin Avci

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data

    (XLS)

    S1 Table. PCR array data.

    This table contains the complete data set from the PRC arrays.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES